Ładuje się......
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda(®)) to submit evidence of its clinical and cost effectiveness for the treatment of patients with r...
Zapisane w:
| Wydane w: | Pharmacoeconomics |
|---|---|
| Główni autorzy: | , , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Springer International Publishing
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6713293/ https://ncbi.nlm.nih.gov/pubmed/30895564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-019-00792-7 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|